REACH-Es: Adapting a Digital Health Tool to Improve Diabetes Medication Adherence Among Latino Adults

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Latino individuals, the fastest growing ethnic minority population in the United States, have a higher prevalence of type 2 diabetes and diabetes-related complications, and are more likely to report inconsistent use of diabetes medications than non-Hispanic White individuals. The proposed project will test an interactive text message-based tool tailored to address barriers to taking diabetes medications that are relevant to Latino adults. If found feasible, acceptable, and usable, this intervention could serve as a scalable tool to improve diabetes management and reduce diabetes-related complications among Latino adults in the United States.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Type 2 diabetes mellitus

• Have current or prior (since 2018) HbA1c ≥8.0%

• Take at least one diabetes medication

• Receive care at MGH- affiliated primary care practices (≥2 visits in the past 3 years)

• ≥18 yrs

• Identify as Latino and/or Hispanic

• Speak and read in Spanish as preferred language

• Willing and able to provide informed consent

• Access to a mobile telephone with text messaging capability

• Suboptimal diabetes medication adherence, assessed using the first 2 items in the Adherence to Refill and Medication Scale (ARMS-d) questionnaire combined: How frequently do you forget or decide to not take your diabetes medications? Participants who answer sometimes, almost always, and/or always will be considered eligible for the study.

Locations
United States
Massachusetts
Massachusetts General Hospital Diabetes Research Center
RECRUITING
Boston
Contact Information
Primary
Jacqueline Seiglie
jseiglie@mgh.harvard.edu
714-588-4791
Time Frame
Start Date: 2024-06-18
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 70
Treatments
Experimental: REACH-Es
Participants in the REACH-Es arm will receive REACH-Es short message service (SMS), as follows: 1) Daily SMS (information related to diet, exercise, self-monitoring of blood glucose, their specific diabetes medication(s), and top 4 medication adherence barriers); 2) Daily two-way SMS (diabetes medication adherence question); 3) Weekly one-way SMS (participants receive weekly feedback on Sunday regarding how many of the last 7 days they took their medicine); 4) A SMS each time an HbA1c is collected with a link to a secure website that displays the result.
Active_comparator: Enhanced treatment as usual (ETAU)
Participants will maintain care as usual (medication treatment and physician monitoring) in addition to a welcome SMS following enrollment, a SMS each time an HbA1c is collected with a link to a secure website that displays the result, and bi-monthly information on diabetes self-care education.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: Massachusetts General Hospital

This content was sourced from clinicaltrials.gov